2 results
D.1 Efficacy, safety, and tolerability of subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy: results from the ADHERE trial
- Z Siddiqi, JA Allen, I Basta, C Eggers, J Guptill, K Gwathmey, C Hewamadduma, E Hofman, Y Hussain, S Kuwabara, F Leypoldt, J Lin, M Lipowska, M Lowe, G Lauria Pinter, L Querol, N Suresh, T Chang, A Tse, P Ulrichts, PA van Doorn, B Van Hoorick, R Yamasaki, RA Lewis
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 51 / Issue s1 / June 2024
- Published online by Cambridge University Press:
- 24 May 2024, pp. S8-S9
-
- Article
-
- You have access Access
- Export citation
-
Background: Efgartigimod, a human immunoglobulin G (IgG)1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing pathogenic IgG autoantibody levels. ADHERE assessed the efficacy and safety of efgartigimod PH20 subcutaneous (SC; co-formulated with recombinant human hyaluronidase PH20) in chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: ADHERE enrolled participants with CIDP (treatment naive or on standard treatments withdrawn during run-in period) and consisted of open-label Stage A (efgartigimod PH20 SC once weekly [QW]), and randomized (1:1) Stage B (efgartigimod or placebo QW). Primary outcomes were clinical improvement (assessed with aINCAT, I-RODS, or mean grip strength; Stage A) and time to first aINCAT score deterioration (relapse; Stage B). Secondary outcomes included treatment-emergent adverse events (TEAEs) incidence. Results: 322 participants entered Stage A. 214 (66.5%) were considered responders, randomized, and treated in Stage B. Efgartigimod significantly reduced the risk of relapse (HR: 0.394; 95% CI: 0.25–0.61) versus placebo (p=0.000039). Reduced risk of relapse occurred in participants receiving corticosteroids, intravenous or SC immunoglobulin, or no treatment before study entry. Most TEAEs were mild to moderate; 3 deaths occurred, none related to efgartigimod. Conclusions: Participants treated with efgartigimod PH20 SC maintained a clinical response and remained relapse-free longer than those treated with placebo.
Family Functioning and Executive Functions among ADHD Children
- W. Walenista, B. Izydorczyk, K. Sitnik-Warchulska, I. Markevych, C. Baumbach, Y. Mysak, M. Szwed, M. Lipowska
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S278
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
ADHD is one of the most frequently diagnosed neurodevelopmental disorders and affects the daily functioning of families raising children with this condition. Among the symptoms typical for ADHD, low effectiveness of executive functions can determine the quality of family life.
ObjectivesThis study aimed to specify whether family communication and satisfaction as reported by a parent are predictors of a child’s executive functioning quality and whether ADHD severity lies on the pathway between the two. Moreover, the child’s sex effect was checked.
MethodsThe study included 200 Polish participants (nGirls = 56) from the NeuroSmog project aged 10-13 diagnosed with ADHD according to the ICD-11. Stanford-Binet 5 Intelligence Scale, PU1 Cognitive Diagnosis Battery, Conners 3 ADHD Diagnosis Questionnaire, and the FACES IV Questionnaire were used to derive needed information. Structural equation modelling (SEM) was applied to test the hypotheses.
ResultsThe quality of family communication and satisfaction did not predict the child’s executive functioning of ADHD children and ADHD severity did not play a mediating role. No differences by sex were observed. We only found a significant effect between IQ and executive functioning level in the general sample (standardized β = X, p = Y) and in girls (-0,24, 0,007).
ConclusionsThese results contrast with previous studies from other cultural contexts that have shown the existence of the hypothesized interrelations. Further research should confirm or refute these observations.
Disclosure of InterestW. Walenista Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, B. Izydorczyk Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, K. Sitnik-Warchulska Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, I. Markevych Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, C. Baumbach Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, Y. Mysak Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, M. Szwed Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme, M. Lipowska Grant / Research support from: the TEAM-NET programme of the Foundation for Polish Science, co-financed from EU resources, obtained from the European Regional Development Fund under the Smart Growth Operational Programme.
![](/core/cambridge-core/public/images/lazy-loader.gif)